What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

PUBLISHER: IMARC | PRODUCT CODE: 1722643

PUBLISHER: IMARC | PRODUCT CODE: 1722643

Antifibrinolytic Drugs Market Report by Indication, Form, End User, and Region 2025-2033

PUBLISHED: May 1, 2025

PAGES: 140 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

The global antifibrinolytic drugs market size reached USD 17.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.0 Billion by 2033, exhibiting a growth rate (CAGR) of 3.77% during 2025-2033.

Antifibrinolytic drugs refer to the pharmaceutical medicines used for promoting the formation of blood clots to prevent fibrinolysis or blockage in arteries and veins. These drugs inhibit the activation of plasminogen, thereby preventing the lysis of fibrin and maintaining clot stability. They are used for the treatment of hemorrhages, vascular tumors and providing relief from heavy menstrual bleeding. They are also used for controlling bleeding during or after invasive surgeries. Some commonly available antifibrinolytic drugs include tranexamic acid, aprotinin, aminocaproic acid and serine protease inhibitors. They are widely used for the management of mucosal bleeding in the oropharynx, nose, gastrointestinal (GI) tract and uterine-vaginal linings. As a result, they are extensively used across hospitals, clinics and trauma and ambulatory surgical centers.

Antifibrinolytic Drugs Market Trends:

The rising incidence of road accidents, traumas and various bleeding disorders is one of the key factors driving the growth of the market. Moreover, the widespread adoption of antifibrinolytic drugs to prevent blood loss in women suffering from menorrhagia and during cardiovascular and neurosurgeries is providing a thrust to the market growth. Antifibrinolytic drugs are essential for preventing clot lysis and minimizing blood loss. In line with this, increasing health consciousness and awareness among the masses regarding the available treatment alternatives for hereditary angioedema and hemophilia are also contributing to the growth of the market. Various technological advancements and the increasing utilization of antifibrinolytic therapy to reduce transfusion in orthopedic patients are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing innovative oral and intravenous drug variants with enhanced efficacy and bio-absorbability. Other factors, including the rising geriatric population and significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Indication:

Gynecology
Hereditary Angioedema
Fibrinolytic Response Testing
Surgeries
Others

Breakup by Form:

Oral
Injectable

Breakup by End User:

Hospitals and Clinics
Ambulatory Surgical Centers
Trauma Centers
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc. and Vitruvias Therapeutics Inc.

Key Questions Answered in This Report

1.How big is the antifibrinolytic drugs market?
2.What is the expected growth rate of the global antifibrinolytic drugs market during 2025-2033?
3.What are the key factors driving the global antifibrinolytic drugs market?
4.What has been the impact of COVID-19 on the global antifibrinolytic drugs market?
5.What is the breakup of the global antifibrinolytic drugs market based on the indication?
6.What are the key regions in the global antifibrinolytic drugs market?
7.Who are the key players/companies in the global antifibrinolytic drugs market?

Product Code: SR112025A5672

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Antifibrinolytic Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Indication

6.1 Gynecology
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Hereditary Angioedema
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Fibrinolytic Response Testing
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Surgeries
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Form

7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Injectable
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Ambulatory Surgical Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Trauma Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 ACIC Pharmaceuticals Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 Akorn Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Aurobindo Pharma Limited
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
- 14.3.4 Ferring Pharmaceuticals
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Novartis AG
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Pfizer Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Takeda Pharmaceutical Company Limited
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Viatris Inc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
- 14.3.9 Vitruvias Therapeutics Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio

Product Code: SR112025A5672

List of Figures

Figure 1: Global: Antifibrinolytic Drugs Market: Major Drivers and Challenges
Figure 2: Global: Antifibrinolytic Drugs Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Antifibrinolytic Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Antifibrinolytic Drugs Market: Breakup by Indication (in %), 2024
Figure 5: Global: Antifibrinolytic Drugs Market: Breakup by Form (in %), 2024
Figure 6: Global: Antifibrinolytic Drugs Market: Breakup by End User (in %), 2024
Figure 7: Global: Antifibrinolytic Drugs Market: Breakup by Region (in %), 2024
Figure 8: Global: Antifibrinolytic Drugs (Gynecology) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Antifibrinolytic Drugs (Gynecology) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Antifibrinolytic Drugs (Hereditary Angioedema) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Antifibrinolytic Drugs (Hereditary Angioedema) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Antifibrinolytic Drugs (Fibrinolytic Response Testing) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Antifibrinolytic Drugs (Fibrinolytic Response Testing) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Antifibrinolytic Drugs (Surgeries) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Antifibrinolytic Drugs (Surgeries) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Antifibrinolytic Drugs (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Antifibrinolytic Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Antifibrinolytic Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Antifibrinolytic Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Antifibrinolytic Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Antifibrinolytic Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Antifibrinolytic Drugs (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Antifibrinolytic Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Antifibrinolytic Drugs (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Antifibrinolytic Drugs (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Antifibrinolytic Drugs (Trauma Centers) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Antifibrinolytic Drugs (Trauma Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Antifibrinolytic Drugs (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Antifibrinolytic Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: North America: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: North America: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: United States: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: United States: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Canada: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Canada: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Asia-Pacific: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Asia-Pacific: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: China: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: China: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Japan: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: Japan: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: India: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: India: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: South Korea: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: South Korea: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: Australia: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: Australia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: Indonesia: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: Indonesia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Others: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Europe: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Europe: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Germany: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Germany: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: France: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: France: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: United Kingdom: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: United Kingdom: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: Italy: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: Italy: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: Spain: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: Spain: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Russia: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Russia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Others: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Latin America: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Latin America: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Brazil: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Brazil: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Mexico: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Mexico: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Others: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Middle East and Africa: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Middle East and Africa: Antifibrinolytic Drugs Market: Breakup by Country (in %), 2024
Figure 78: Middle East and Africa: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Global: Antifibrinolytic Drugs Industry: SWOT Analysis
Figure 80: Global: Antifibrinolytic Drugs Industry: Value Chain Analysis
Figure 81: Global: Antifibrinolytic Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Antifibrinolytic Drugs Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Indication (in Million USD), 2025-2033
Table 3: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Form (in Million USD), 2025-2033
Table 4: Global: Antifibrinolytic Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
Table 5: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Antifibrinolytic Drugs Market: Competitive Structure
Table 7: Global: Antifibrinolytic Drugs Market: Key Players